Pathogenetic justification of sacubitril / valsartan use in respiratory-cardial comorbidity

Among the comorbid conditions that significantly worsen quality of life and expectancy are chronic obstructive pulmonary disease heart failure. Difficulties drug therapy mutually exclusive approaches in treatment concomitant cardiovascular pathology. Aim this study was to provide scientific evidence possible use combined LCZ696 (angiotensin receptor neprilysin inhibitor, ARNI), which contains inhibitor sacubitril (AHU377) angiotensin II blocker valsartan, patients with congestive The article presents a review literature. It demonstrated cause mortality could be both changes respiratory system complications system. has been shown progressive leads formation hypertension, right ventricular hypertrophy, decrease its systolic function, subsequent dilatation ventricle, development failure, is one most serious difficult tests process. further such pathology left role natriuretic peptides, namely brain peptide, propeptide, C-type N-terminal precursor as markers failure discussed. Natriuretic peptide currently recognized marker high value achieved for determining prognosis stratification risk acts vasodilator, provides antiproliferative activity through G-dependent protein kinase pathway promotes bronchodilation, causing release acetylcholine from bronchial epithelial cells. Conclusions. All these properties suggest peptides may potential cardiac disease. best way prolong inhibit degradation sacubitril.